Biotech giant Gilead Sciences, Inc.’s GILD shares have risen 44.2% in the past six months compared with the industry’s growth of 1.1%. The stock has also outperformed the sector and the S&P 500. It ...

Bob Valamehr, Ph.D. MBA, To Become President and CEO January 1, 2025Scott Wolchko To Retire as President and CEO after 10 years of Leadership in ...

Ramani Ramchandran, Professor at the Medical College of Wisconsin, investigates ciliary biomarkers for diagnosing and ...

Ladies and gentlemen, thank you for standing by. Welcome to the B.O.S. Conference Call. All participants are at present in ...

Researchers in China have developed a hermetic hydrovoltaic cell that can generate electricity using ambient heat, little ...

Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology/Emory University, Atlanta, United States ...

Use of the anti-CD19 CAR T-cell therapy obecabtagene autoleucel (obe-cel; Aucatzyl) resulted in durable remissions among ...

CARGO Therapeutics (CRGX) stock receives Outperform rating from William Blair due to potential of its lead candidate firicabtagene autoleucel (firi-cel). Read more here.

For CAR T-cell therapies, there were notable additions for its use after 1 and 2 prior lines of therapy, 1 both category 1 ...

Adcendo joins a growing group of biotechs working to usher the next generation of antibody-drug conjugates to the market.

Incyte (Nasdaq: INCY) today announced that the Company will present new data from across its oncology portfolio at the 2024 American Society of Hematology (ASH) Annual Meeting in San Diego. “These ...

ADC Therapeutics, Sutro Biopharma and Zai Lab are among those developing antibody-drug conjugates to address payload and ...